QIAGEN N.V. (QGEN) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:QGEN - NL0015002CX3 - Common Stock
47.75 USD
-0.35 (-0.73%)
47.75 USD
0 (0%)
Overall QGEN gets a fundamental rating of 6 out of 10. We evaluated QGEN against 58 industry peers in the Life Sciences Tools & Services industry. Both the health and profitability get an excellent rating, making QGEN a very profitable company, without any liquidiy or solvency issues. QGEN is not valued too expensively and it also shows a decent growth rate. With these ratings, QGEN could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
In the past year QGEN was profitable.
In the past year QGEN had a positive cash flow from operations.
In the past 5 years QGEN has always been profitable.
In the past 5 years QGEN always reported a positive cash flow from operatings.
1.2 Ratios
QGEN has a better Return On Assets (6.19%) than 82.76% of its industry peers.
QGEN has a better Return On Equity (11.11%) than 82.76% of its industry peers.
QGEN has a better Return On Invested Capital (7.44%) than 79.31% of its industry peers.
The Average Return On Invested Capital over the past 3 years for QGEN is significantly below the industry average of 13.53%.
The last Return On Invested Capital (7.44%) for QGEN is above the 3 year average (7.25%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROIC | 7.44% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
1.3 Margins
With an excellent Profit Margin value of 19.58%, QGEN belongs to the best of the industry, outperforming 94.83% of the companies in the same industry.
QGEN's Profit Margin has declined in the last couple of years.
QGEN has a Operating Margin of 27.02%. This is amongst the best in the industry. QGEN outperforms 96.55% of its industry peers.
QGEN's Operating Margin has improved in the last couple of years.
QGEN has a Gross Margin of 64.10%. This is amongst the best in the industry. QGEN outperforms 86.21% of its industry peers.
QGEN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% |
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
2. Health
2.1 Basic Checks
QGEN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
QGEN has less shares outstanding than it did 1 year ago.
The number of shares outstanding for QGEN has been reduced compared to 5 years ago.
QGEN has a better debt/assets ratio than last year.
2.2 Solvency
QGEN has an Altman-Z score of 3.60. This indicates that QGEN is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.60, QGEN is in the better half of the industry, outperforming 68.97% of the companies in the same industry.
The Debt to FCF ratio of QGEN is 4.50, which is a neutral value as it means it would take QGEN, 4.50 years of fcf income to pay off all of its debts.
With a decent Debt to FCF ratio value of 4.50, QGEN is doing good in the industry, outperforming 72.41% of the companies in the same industry.
QGEN has a Debt/Equity ratio of 0.45. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.45, QGEN is not doing good in the industry: 60.34% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Altman-Z | 3.6 |
ROIC/WACC0.95
WACC7.85%
2.3 Liquidity
A Current Ratio of 2.60 indicates that QGEN has no problem at all paying its short term obligations.
QGEN has a Current ratio of 2.60. This is comparable to the rest of the industry: QGEN outperforms 48.28% of its industry peers.
QGEN has a Quick Ratio of 2.30. This indicates that QGEN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.30, QGEN perfoms like the industry average, outperforming 51.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 9.62% over the past year.
QGEN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 8.40% yearly.
QGEN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.32%.
The Revenue has been growing slightly by 5.32% on average over the past years.
EPS 1Y (TTM)9.62%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%4.04%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
3.2 Future
QGEN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.80% yearly.
The Revenue is expected to grow by 7.89% on average over the next years.
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.8%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.89%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 20.15 indicates a rather expensive valuation of QGEN.
Compared to the rest of the industry, the Price/Earnings ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 87.93% of the companies listed in the same industry.
QGEN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.31, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 18.40, QGEN is valued on the expensive side.
Based on the Price/Forward Earnings ratio, QGEN is valued cheaply inside the industry as 89.66% of the companies are valued more expensively.
QGEN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 36.59.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.15 | ||
| Fwd PE | 18.4 |
4.2 Price Multiples
QGEN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. QGEN is cheaper than 93.10% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of QGEN indicates a rather cheap valuation: QGEN is cheaper than 86.21% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.91 | ||
| EV/EBITDA | 14.05 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates QGEN does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of QGEN may justify a higher PE ratio.
PEG (NY)2.36
PEG (5Y)2.4
EPS Next 2Y8.08%
EPS Next 3Y8.5%
5. Dividend
5.1 Amount
QGEN has a yearly dividend return of 0.55%, which is pretty low.
Compared to an average industry Dividend Yield of 0.48, QGEN pays a better dividend. On top of this QGEN pays more dividend than 94.83% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.40, QGEN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
5.2 History
QGEN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y8.08%
EPS Next 3Y8.5%
47.75
-0.35 (-0.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.95%
Inst Owner Change-18.51%
Ins Owners0.44%
Ins Owner ChangeN/A
Market Cap10.35B
Revenue(TTM)2.07B
Net Income(TTM)405.37M
Analysts74.17
Price Target51.67 (8.21%)
Short Float %2.86%
Short Ratio5.25
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.55% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-2.4%
Max EPS beat(2)2.11%
EPS beat(4)2
Avg EPS beat(4)0.92%
Min EPS beat(4)-3.85%
Max EPS beat(4)7.8%
EPS beat(8)5
Avg EPS beat(8)1.59%
EPS beat(12)8
Avg EPS beat(12)2.59%
EPS beat(16)12
Avg EPS beat(16)5.18%
Revenue beat(2)0
Avg Revenue beat(2)-0.42%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.12%
Revenue beat(4)1
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.43%
Revenue beat(8)1
Avg Revenue beat(8)-0.6%
Revenue beat(12)2
Avg Revenue beat(12)-0.64%
Revenue beat(16)6
Avg Revenue beat(16)0.46%
PT rev (1m)-1.37%
PT rev (3m)-1.98%
EPS NQ rev (1m)-1.93%
EPS NQ rev (3m)-1.69%
EPS NY rev (1m)0%
EPS NY rev (3m)0.63%
Revenue NQ rev (1m)-1.91%
Revenue NQ rev (3m)-1.91%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.15 | ||
| Fwd PE | 18.4 | ||
| P/S | 5 | ||
| P/FCF | 21.91 | ||
| P/OCF | 15.74 | ||
| P/B | 2.84 | ||
| P/tB | 12.98 | ||
| EV/EBITDA | 14.05 |
EPS(TTM)2.37
EY4.96%
EPS(NY)2.6
Fwd EY5.44%
FCF(TTM)2.18
FCFY4.56%
OCF(TTM)3.03
OCFY6.35%
SpS9.55
BVpS16.83
TBVpS3.68
PEG (NY)2.36
PEG (5Y)2.4
Graham Number29.96
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.19% | ||
| ROE | 11.11% | ||
| ROCE | 10.03% | ||
| ROIC | 7.44% | ||
| ROICexc | 10.67% | ||
| ROICexgc | 39.98% | ||
| OM | 27.02% | ||
| PM (TTM) | 19.58% | ||
| GM | 64.1% | ||
| FCFM | 22.82% |
ROA(3y)4.59%
ROA(5y)5.65%
ROE(3y)7.84%
ROE(5y)10.58%
ROIC(3y)7.25%
ROIC(5y)7.96%
ROICexc(3y)9.42%
ROICexc(5y)10.13%
ROICexgc(3y)34.6%
ROICexgc(5y)42.77%
ROCE(3y)9.77%
ROCE(5y)10.73%
ROICexgc growth 3Y-31.24%
ROICexgc growth 5Y-2.41%
ROICexc growth 3Y-13.09%
ROICexc growth 5Y6.48%
OM growth 3Y-5.04%
OM growth 5Y4.09%
PM growth 3Y-42.96%
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.63%
F-Score8
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.45 | ||
| Debt/FCF | 4.5 | ||
| Debt/EBITDA | 2.17 | ||
| Cap/Depr | 97.52% | ||
| Cap/Sales | 8.94% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 87.76% | ||
| Profit Quality | 116.56% | ||
| Current Ratio | 2.6 | ||
| Quick Ratio | 2.3 | ||
| Altman-Z | 3.6 |
F-Score8
WACC7.85%
ROIC/WACC0.95
Cap/Depr(3y)78.4%
Cap/Depr(5y)95.94%
Cap/Sales(3y)7.97%
Cap/Sales(5y)9.87%
Profit Quality(3y)273.85%
Profit Quality(5y)189.74%
High Growth Momentum
Growth
EPS 1Y (TTM)9.62%
EPS 3Y-6.66%
EPS 5Y8.4%
EPS Q2Q%4.04%
EPS Next Y8.55%
EPS Next 2Y8.08%
EPS Next 3Y8.5%
EPS Next 5Y8.8%
Revenue 1Y (TTM)5.32%
Revenue growth 3Y-4.22%
Revenue growth 5Y5.32%
Sales Q2Q%6.09%
Revenue Next Year5.25%
Revenue Next 2Y5.45%
Revenue Next 3Y5.86%
Revenue Next 5Y7.89%
EBIT growth 1Y18.55%
EBIT growth 3Y-9.05%
EBIT growth 5Y9.63%
EBIT Next Year57.27%
EBIT Next 3Y22.23%
EBIT Next 5Y15.78%
FCF growth 1Y71.67%
FCF growth 3Y5.12%
FCF growth 5Y55.1%
OCF growth 1Y52.1%
OCF growth 3Y1.77%
OCF growth 5Y15.28%
QIAGEN N.V. / QGEN FAQ
Can you provide the ChartMill fundamental rating for QIAGEN N.V.?
ChartMill assigns a fundamental rating of 6 / 10 to QGEN.
What is the valuation status of QIAGEN N.V. (QGEN) stock?
ChartMill assigns a valuation rating of 6 / 10 to QIAGEN N.V. (QGEN). This can be considered as Fairly Valued.
What is the profitability of QGEN stock?
QIAGEN N.V. (QGEN) has a profitability rating of 8 / 10.
What are the PE and PB ratios of QIAGEN N.V. (QGEN) stock?
The Price/Earnings (PE) ratio for QIAGEN N.V. (QGEN) is 20.15 and the Price/Book (PB) ratio is 2.84.